Jonathan Zalevsky sold $336K of Nektar Therapeutics (NKTR)

Executed Jun 15, disclosed Jun 17, 2 days later.

Value, as filed

$336K

5,538 sh × $60.71

Executed

Jun 15

the trade date, as filed

Disclosed

Jun 17

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Jonathan Zalevsky Chief R&D Officer profile →

Jonathan Zalevsky (Chief R&D Officer) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in Nektar Therapeutics (NKTR). The largest single filing was $398K of NKTR (5,681 sh × $70.00, as filed), executed Jun 30.

The name

NKTR

Nektar Therapeutics NKTR · Healthcare · 7 filings in 24 months ticker →

Healthcare · Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the Unit…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Jonathan Zalevsky in NKTR

NKTRSALE Nektar Therapeutics $398K
5,681 sh × $70.00
Exec Jun 30
Filed Jul 2 · 7:06 PM ET NKTRSALE Nektar Therapeutics $138K
3,867 sh × $35.67
Exec Jan 20
Filed Jan 22 · 5:30 PM ET